Objectives To investigate how individual rheumatoid arthritis (RA) autoantibodies associate with individual signs and symptoms at the time of RA diagnosis. Methods IgA, IgG, IgM rheumatoid factor (RF) ...

Objective In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent ...

Correspondence to Dr Tristan Maerz, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; tmaerz{at}med.umich.edu Objectives Synovium is acutely affected following joint ...

Objectives To develop evidence-based recommendations for management of calcium pyrophosphate deposition (CPPD). Methods A multidisciplinary guideline development group of 15 experts, representing 10 ...

22 Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Objectives To develop EULAR recommendations for screening and prophylaxis of chronic and opportunistic ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition characterised by heterogeneous clinical features. The patients with SLE are known to have an increased risk of cardiovascular ...

3 Horizon Clinical Research, Grossmont Orthopedic Medical Group, San Diego, United States of America 4 Rush University Medical Center, Department of Orthopedics, Chicago, United States of America ...

Objective To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA). Methods Patients with vasculitis or comparator diseases were recruited into an ...

Synovial fluids can contain a number of crystals and other particulate matter. Some of these, particularly monosodium urate monohydrate (MSUM) and calcium pyrophosphate dihydrate (CPPD) crystals, are ...

Objectives To report the level and trends of prevalence, incidence and years lived with disability (YLDs) for osteoarthritis (OA) in 195 countries and territories from 1990 to 2017 by age, sex and ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...

23 NIHR University College London Hospitals Biomedical Research Centre, University College London Hospitals (UCLH) NHS Foundation Trust, London, UK Methods Following the EULAR Standardised Operating ...